The US Patent Trial and Appeal Board has ruled against Mylan in its attempts to force a patent review of Bayer's blood clot disorder treatment. Mylan claimed the patent didn’t cover a new invention, and filed a petition for review after Bayer and partner Johnson & Johnson sued to prevent Mylan from selling a generic version of the drug. In the ruling, which was published on Monday, the board said that it had found no evidence that Bayer or any other company had infringed on patents held by Mylan.
The US Patent Trial and Appeal Board has ruled against Mylan in its attempts to force a patent review of Bayer's blood clot disorder treatment. In the ruling, which was published on Monday, the board said that it had found no evidence that Bayer or any other company had infringed on patents held by Mylan.